Company intelligence / Profile preview
Lamellar Biomedical
Bellshill/Glasgow, Scotland, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Lamellar Biomedical developed a proprietary nanotechnology-based drug delivery platform called Lamellasome™, designed to alter mucus properties, disperse biofilms, and fight infection. Their lead programs targeted severe respiratory conditions such as cystic fibrosis and idiopathic pulmonary fibrosis. The company advanced at least one program into clinical trials but was dissolved in May 2024.
- Therapeutic areas
- PulmonologyOther
- Modalities
- Gene therapymiRNA-based therapyNanoparticleSmall moleculeMedical device
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; no major pharma partnerships identified in available sources.
Beyond the preview
Go deeper on Lamellar Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lamellar Biomedical.